"I'm sorry he took one life, but please don't take another." In closing statements, attorney Arie Bax asked the jury of three men and eight women to consider whether his client shot Holmes for revenge or because he feared for his life and his …
Who Is Watching Baxter International in March 2018? For fiscal 2018, Baxter International (BAX) changed its reporting structure from the previous year. The company has two segments—Hospital Products and Renal—with a …
In this study, we found that CtBP represses Bcl-2-associated X protein (Bax) transcription in glucose-rich media by binding to the E-box region of the Bax promoter. Glucose withdrawal leads to the dissociation of CtBP from the Bax promoter …
Cesca Therapeutics Inc. is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is engaged in developing and manufacturing of automated blood and …
Vale S.A. (NYSE: VALE) and China Merchants Energy Shipping Co., Ltd. (CMES), a subsidiary of China Merchants …
Equity securities primarily consist of common stock- preferred stock- securities convertible into common stock- or securities or other instruments whose price is linked to the value of common stock. The fund focuses primarily on …
Quest Diagnostics currently carries a Zacks Rank #3 (Hold). Better ranked medical stocks are NxStage Medical Inc. NXTM, Baxter International Inc. BAX and Bovie Medical Corporation BVX. NxStage Medical and Baxter International …
Baxter International Inc : Company provides financial outlook for 2018 and 2020 . Expects to grow sales 3 to 4 percent on a compounded annual basis at constant currency rates from 2016 through 2018 . Expects a 2018 adjusted operating …
After rising 19% yesterday on takeover speculation, shares of Brocade Communications (Nasdaq: BRCD) are flat today. Yesterday, the Wall Street Journal reported that Brocade has quietly put itself up for sale with potential buyers …
Baxter International Inc. (BAX) entered a global licensing agreement with Cell Therapeutics, Inc. (CTIC) to jointly develop and commercialize JAK2/FLT3 inhibitor pacritinib that fights against genetic mutations linked to myelofibrosis, leukemia …